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ABSTRACT
Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation that includes
Crohn´s disease (CD) and ulcerative colitis (UC). Although the etiology is still unknown, some
specific factors have been directly related to IBD, including genetic factors, abnormal intestinal
immunity, and/or gut microbiota modifications. Recent findings highlight the primary role of the
gut microbiota closely associated with a persistent inappropriate inflammatory response. This gut
environment of dysbiosis in a susceptible IBD host can increasingly worsen and lead to coloniza-
tion and infection with some opportunistic pathogens, especially Clostridium difficile. C. difficile is
an intestinal pathogen considered the main cause of antibiotic-associated diarrhea and colitis and
an important complication of IBD, which can trigger or worsen an IBD flare. Recent findings have
highlighted the loss of bacterial cooperation in the gut ecosystem, as well as the pronounced
intestinal dysbiosis, in patients suffering from IBD and concomitant C. difficile infection (CDI). The
results of intestinal microbiota studies are still limited and often difficult to compare because of
the variety of disease conditions. However, these data provide important clues regarding the main
modifications and interrelations in the complicated gut ecosystem to better understand both
diseases and to take advantage of the development of new therapeutic strategies. In this review,
we analyze in depth the gut microbiota changes associated with both forms of IBD and CDI and
their similarity with the dysbiosis that occurs in CDI. We also discuss the metabolic pathways that
favor the proliferation or decrease in several important taxa directly related to the disease.
ARTICLE HISTORY
Received 7 August 2019
Revised 20 January 2020







Clostridium (Clostridioides) difficile is a worldwide
public health concern and is considered the major
cause of antibiotic-associated infections in healthcare
settings. It is responsible for serious outbreaks of hos-
pital-acquired infections and for several sporadic diar-
rheas in the community. The pathogen is a sporulating,
strictly anaerobic bacterium, and transmission occurs
mainly by the fecal-oral route. Intestinal colonization
and toxin production are necessary to trigger the infec-
tion; therefore, the disease is strongly related to the
disruption of the gut microbiome1.
Inflammatory bowel disease (IBD) is a chronic
disease of mainly the intestinal tract that includes
ulcerative colitis (UC) and Crohn´s disease (CD).
UC is a diffuse, continuous, and nonspecific inflam-
mation of the colonic mucosa proximal to the rec-
tum. Crohn´s disease is a chronic granulomatous
inflammation that affects the entire digestive tract,
especially the ileocaecum and perianal regions.
While the cause of both disease forms is still
unknown, some specific factors have been directly
related to IBD, including genetic factors, abnormal
intestinal immunity, and gut microbiota modifica-
tions directly caused by diet or infections.2
Patients suffering from IBD are particularly
susceptible to C. difficile infection (CDI), with
an increase in morbidity and mortality.3 Even if
it is not clear if IBD itself or disease activity is an
independent risk factor for CDI,3,4 further pre-
disposing and specific conditions have been
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suggested in these patients,3 including colectomy
and ileal-anal pouch anastomosis,5 nonsteroidal
anti-inflammatory drugs,6 proton pump inhibi-
tors, and other immunosuppressant treatments.7
Recurrence of CDI is common in IBD,8 and in
the most complicated cases, only gut ecosystem
restoration by fecal microbiota transplantation
can help to break the cycle of recurrence.9 In
the last decade, the availability of new omic tech-
nologies has allowed the investigation of gut
microbial communities to identify whether any
change in the bacterial composition is involved
in CDI or an IBD flare.
This review analyses all the latest findings about the
specific role of the gut microbiota composition in
intestinal inflammation and infection. We will also
focus on the decrease in gut diversity and its causative
role in the development of CDI in patients suffering
from IBD. Finally, we will link all these modifications
in the gut with the production ofmicrobial metabolites
and their role in the worsening of CDI and IBD.
A brief history of concomitant CDI and IBD
The history of C. difficile dates back to 1935
(Figure 1), when the bacterium was isolated for
the first time from the feces of breastfed infants.10
Despite the interest that the bacterium aroused in
the following years, it was not until 1978 that it
was first associated with pseudomembranous coli-
tis and previous antibiotic therapy.11,12 First,
immunological studies of ulcerative colitis
observed the increase in anti-colon antibody titers
due not only to chronic colon alteration, but also
to unrelated gastrointestinal diseases, such as those
caused by C. difficile, Staphylococcus aureus,
Forsman antigen or Escherichia coli (E. coli) 014.
These early findings showed that some antigens,
especially those from E. coli 014, may contribute to
colon autoimmunity in ulcerative colitis through
disruption of tolerance.13 In 1980, two studies that
were published in the literature almost simulta-
neously described for the first time the presence
of C. difficile toxins in patients with IBD during
a symptomatic relapse and suggested the associa-
tion of these toxins with further complications in
chronic disease or even with an IBD flare.14,15 In
the following years, several other reports docu-
mented the possible association between CDI and
IBD, and different studies began to investigate
more specifically the role of C. difficile and its
toxins, differentiating patients with UC and CD,
although the results were not always the same or
conclusive.16–18 Some studies directly associated
the bacterium with toxic megacolon, acute relapses
of IBD and/or hospital admissions.19,20 However,
other further studies began to question the role of
C. difficile in both forms of IBD, suggesting that
the bacterium could be a part of the bowel gut,
without specific cytopathic effects in the intestinal
tissues of these patients, and that it would be
relevant in only specific cases with previous anti-
microbial therapies.21,22 The diversity in C. difficile
detection methods used at the time varied greatly
among the different studies, and they were not
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Figure 1. Early history of concomitant CDI and IBD.
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clinical evidence of the role of C. difficile in IBD
patients was scarce.24
During the 1990s, a few studies were published
reporting the presence of toxigenic C. difficile in the
feces of IBD patients, with a prevalence that varied
strongly up to 32%, and they described an exacerba-
tion of the disease with the presence of the
bacterium.25,26 However, it was not until the 2000s
when there is an important growth in the number of
publications that focused repeatedly on the impact of
CDI in patients with IBD.27–29 This growing interest
concurred with several outbreaks of CDI in hospitals
in Europe and in the United States, and it is at this
moment when C. difficile went from being an intest-
inal pathogen associated with antibiotic therapy to
being the most important cause of nosocomial diar-
rhea in humans.30 Therefore, it seems logical that the
IBD population was also increasingly affected by this
pathogen, as reflected in the literature, with signifi-
cant morbidity andmortality.31 Other additional but
not mutually exclusive possibilities to explain the
increase in the incidence of CDI in IBD patients in
the last two decades are the evolution of the detec-
tion methods for the bacterium, the rapid diagnosis
of the infection and a change in the epidemiology,
with the emergence of new, best adapted, hyperviru-
lent, and multidrug-resistant strains.32,33
In addition to epidemiological and clinical studies
addressing the impact of CDI in IBD patients, in the
last decade, several studies have investigated the
interplay between the gut microbiota and disease.
Advances in culture-independent molecular meth-
ods have allowed the identification of these bacterial
populations present in the gut at each phase of the
disease, which is followed by the use of new promis-
ing therapies, such as fecal microbiota transplanta-
tion or diet strategies (including prebiotics and
probiotics), to successfully treat both of the diseases.
Gut microbial community imbalances in
human IBD
In IBD patients, intestinal tissue alteration by bacteria
and/or inflammation results in a favorable environ-
ment with readily available nutrient sources leading to
important perturbations in the normal composition
of gut bacteria, in their functions, and finally in their
metabolism. These alterations are potential precursors
of other concomitant infections, including not only
CDI but also other bacterial enteric pathogens, e.g.,
cytomegalovirus, enteroviruses, Mycoplasma pneu-
moniae, and upper respiratory viruses, and
Entamoeba histolytica, among others. This perturba-
tion finally triggers an important relapse or exacerba-
tion of IBD symptoms.34
The results of intestinal microbiota studies are
often difficult to compare due to different factors,
including patient´s variability or the analysis meth-
ods and techniques used. Different sequencing tech-
nologies, annotation tools, and statistical analysis
have been developed to study the microbial diversity
and changes in the gut ecosystem. Several
recent reviews on metagenomics (from sampling to
data analysis) are already available in the literature35
and they show the need for a standardization of
analysis techniques and workflows, in order to
avoid variability in the results related to the metho-
dology of the study.
Regarding patients, the variety of disease treat-
ments (such as surgical interventions, anti-
inflammatory drugs, biologics, immunosuppressant
treatments, corticosteroids, proton pump inhibitors
or antibiotics) and the demographical characteristics
of the study population (gender, age, other overlap-
ping syndromes, diet, smoking history, etc.) could
have a direct impact on the results obtained.36–39 For
example, it was reported that liver diseases could be
the primary factors associated with disease-specific
dysbiotic influences of IBD patients.36 Disease phe-
notypes (including IBD extent or activity) have also
been associated with important changes in the gut
mucosa, especially in CD,39 while other study
observed no significant changes in the gut micro-
biota of UC patients after the use of biologic treat-
ment (infliximab, adalimumab, or golimumab).36
Other described factors that influence the intestinal
bacterial structure are the sample origin (stool or
biopsy), as well as the biopsy location, which can
induce other changes.37,38 In this context, it has been
observed that the microbial imbalance due to intest-
inal inflammation is not always reflected in the
lumen or in the stool. Therefore, a complementary
analysis of tissue biopsies would be necessary to
identify disease biomarker signals.40
Despite all these interindividual, sample, or metho-
dological factors, the recovery of consistent changes in
the bacterial composition, which are repeatedly
reported in different studies investigating IBD patients,
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can highlight disease-specific bacterial signatures. It
has also been suggested that changes in gut bacterial
communities are not only a consequence of inflamma-
tion but also possible primary factors in disease.37
These changes could be interpreted as promising bio-
markers, noninvasive diagnostic tools or new thera-
peutic approaches.
Ulcerative colitis
General disruption of gut homeostasis in patients
with UC is characterized by a depleted mucous
layer (loss of mucus-containing goblet cells),
a decrease in microbial alpha diversity,36,41 an
increase in bacterial penetration, and an exaggerated
Ig response, especially for IgA and IgG.37 Recently,
all these changes were observed in both inflamed and
non-inflamed intestinal sections of pediatric UC
patients, suggesting that they are not a result of
inflammation but rather precede (and probably pro-
mote) the disease.37 However, it remains unclear if
the decrease in bacterial diversity is the cause or the
result of the depleted mucus layer.37 Differences in
bacterial diversity have been found when UC groups
are compared with control individuals.36,41,42 The
global microbiota composition was shifted by the
presence of UC, with a reduced number of species
and diminished richness and evenness, with an
alteration in the community composition and
structure.41 However, these findings can also be
observed in both forms of IBD.40,41.
Specific gut microbiota signatures have been
detected in patients suffering from UC. These
changes include a decrease in the abundance of the
phylum Verrucomicrobia36 or a decrease in the
family Leuconostocaceae, the latter being known as
acetate and lactate producers38. There is not a clear
consensus proportion of the genus Bacteroides
within the phylum Bacteroidetes. While some stu-
dies in the literature reported significant reduction in
Bacteroides,42 further studies found that this group is
increased in UC patients43 and directly associated
with the degradation of acid mucin as a carbon
source in the colon, with an exaggerated inflamma-
tory response and with colitis.37 Regarding the
Clostridia class (phylum Firmicutes), we found
some differences between families and genera, espe-
cially for the Clostridiaceae, Ruminococcaceae, and
Lachnospiraceae families.36–39,44 In UC, studies have
reported a reduction in the proportions of the genus
Coprococcus and some species of genus Roseburia,
along with other genera and species belonging to the
family Lachnospiraceae.36,39 In contrast, for the
Clostridiaceae family, some species seem to be in
increased proportions in these patients,37 like
Clostridium symbiosum, while a reduction in
the abundance of other groups, such as Clostridium
colinum and Clostridium subcluster XIVab, has
also been described.36,42 Additionally, in the
order Clostridiales, a decrease in the genus
Phascolarctobacterium was linked to the presence
of colonic inflammation regardless of the UC
phenotype36,38 (Tables 1 and 2).
Crohn's disease
Most of the microbiota changes previously described
in the gut microbiota of patients with UC are also
observed in patients suffering from CD. For exam-
ple, an increase in the proportion of the
Enterobacteriaceae family is found in UC patients,
which is also present in the gut of patients suffering
from CD,43,47,68 especially regarding Escherichia and
Shigella relative proportions, which are directly
implicated in intestinal inflammation.38,39,61
In CD patients with ileal involvement, an impor-
tant reduction in the proportions of
Ruminococcaceae and Faecalibacterium has been
reported in several studies (Table 1). They are recog-
nized as acetate and butyrate producers, respectively,
and therefore they contribute to creating an envir-
onment of oxidative stress in the intestine38
(Figure 2). In this context, while some bacteria
seem to be associated with a specific disease pheno-
type, a decrease in Clostridiales is most likely present
in all forms of CD39,47,48,51,54,59,63 with only a few
exceptions.61 In contrast, there is no unanimity
regarding the increase or decrease in
Lachnospiraceae abundance in CD. While some stu-
dies reported an increase in the proportions of this
family in the intestinal mucosa of patients with
moderate activity,37 further studies reported
a decrease in their proportions38,40,52,61 or an
increase at the family level but a depletion in lower
taxonomical levels.46 These findings may indicate an
important correlation between intestinal dysbiosis
and CD phenotype39 (Tables 1 and 2).

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 C. RODRÍGUEZ ET AL.
Dysbiosis implications
At this point, we can observe that the available
studies in the literature have described more simi-
larities than dissimilarities in the gut environment
of IBD patients, regardless of whether they suffer
from CD or UC. Furthermore, the proportions of
some phylum seem to vary in function of the
compartments of the intestinal tract, notably in
ileal, colonic tissue, and rectal tissue.69
The decrease in the alpha-diversity index and the
increase or decrease in the different taxa in the gut
have important functional implications for epithelium
repair and inflammation regulation, playing
a fundamental role in the course and worsening of
the disease. The crosstalk of the bacterial groups in the
gut ecosystem is a competitive, bidirectional, and
dynamic process, which evolves in the function of
the local environment. In turn, this environment
directly depends on the available nutrients and the
bacterial metabolites, which finally promotes differ-
ential bacterial growth. In IBD individuals, a decrease
in basic biosynthesis has been observed, along with
changes in several other metabolic processes (the
biosynthesis of essential amino acids, cobalamin
synthesis, purine and pyrimidine biosynthesis, aceto-
genesis to replace biomethanation, lipid catabolism,
and phospholipidmetabolism).38–40 Under these con-
ditions, the levels of hydrogen are strongly reduced,
promoting an increase in aerobic and aerotolerant
taxa and exacerbating disease severity.40
Proteobacteria phylum in IBD patient:
enterobacteriaceae, pasteurellaceae, and
desulfovibrionaceae families
Several studies have reported an increase in the
Pasteurellaceae and/or Enterobacteriaceae families in
patients with CD.37–40,45-47,49,68 Gut inflammation and
chronic colitis have been further associated with an
important increase of Enterobacteriaceae family68 and
an oxidative stress in the gut. A recent study goes
beyond and suggests Enterobacteriaceae as stool bio-
markers in IBD.45 There are several metabolic changes
that promote oxidative stress at the mucosal surface of
IBD patients and favor an increased level or depletion
of different taxa that use mucin as a primary energy
source.37,38 Specifically, the increase in components of















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10 C. RODRÍGUEZ ET AL.
fluorobenzoate degradation) seems to be directly asso-
ciated with Enterobacteriaceae growth, virulence, and
stress response.40 Bacteria such as Salmonella or enter-
ohemorrhagic E. coli would take advantage of these
redox stresses and therefore proliferate to a large
extent. Indeed, in the ileum mucosa of CD patients
and in the fecal samples of UC patients,60 high num-
bers of adherent and invasive E. coli have been found,
as well as a high prevalence of antibodies directed
against E. coli outer membrane porin C (OmpC) and
flagellin. It seems that E. coli acts as an opportunistic
pathogen and is directly implicated in the disease, with
the induction of the production of cytokines, such as
tumor necrosis factor α (TNFα) and IL8,39 and an
increase in mucin degradation.
In contrast, the Desulfovibrionaceae family is
reported in reduced proportions,37 with a negative
correlation between physiological distress and its
abundance.70 The genus Desulfovibrio degrades acidic
mucin normally found in the colon. However, in CD
patients, the mucus is mostly neutral, which can
explain the reductions observed in these subjects.37
Bacteroidetes pylum in IBD patients:
prevotellaceae and bacteroidaceae families
In IBD patients, inflammation and colitis have been
also associated with an increase of Prevotellaceae43,51
and Bacteroidaceae46 family. Within the latter,
Bacteroides genus has been suggested as an IBD biopsy
biomarker.45
There is an important increase in other bac-
terial-mediated processes, which in turns favor
the proliferation of members of Bacteroidetes
phylum. These processes include an increase in
the metabolism of the sulfur amino acid
cysteine, riboflavin metabolism, lipopolysacchar-
ide production, glutathione biosynthesis,
N-acetylgalactosamine phosphotransferase trans-
porters, and virulence factor production.
A decrease in proportions of Bacteroides genus
has been reported in inflamed mucosa when
compared with non-inflamed mucosa of patients
suffering IBD,49 and have been identified as
a predictor of relapse.54
Firmicutes phylum in IBD patients: clostridiaceae,
lachnospiraceae ruminococcaceae and
veillonellaceae families
The oxidative stress previously described
has also a direct impact in the phylum
Firmicutes, with an increase in some mucolytic
bacteria, especially Ruminococcus torques and
Ruminococcus gnavus.67 A previous study
showed differences in their abundance in the
Figure 2. Changes in the gut microbiota communities of IBD patients.
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dysbiotic gut of CD and CU patients.62
Furthermore, R. gnavus along with Clostridium
hathewayi and Clostridium bolteae have
increased expression during dysbiosis, suggesting
that they could have a role in the disease.62
On the other hand, a decrease in the abundance
of butyrate-producing, hydrogen-utilizing bacteria
and other taxa with anti-inflammatory activity,
including Faecalibacterium, Phascolarctobacterium
(Veillonellaceae family), and Clostridia clades IV
and XIVa, especially the genera Roseburia
(Lachnospiraceae family) and Butyricicoccus
(Clostridiaceae family) have been observed
(Table 1). Species of Roseburia are butyrate pro-
ducers and acetate consumers and are associated
with anti-inflammatory regulatory T cell produc-
tion, while Phascolarctobacterium species are only
succinate consumers. Both of these genera have
been associated with a decrease in butyrate and
propionate production in both forms of IBD.36,38
In relation to the genus Faecalibacterium, a low
rate of Faecalibacterium prausnitzii have been
identified as predictors of relapse.54 IBD inflamed
mucosa presents a decrease in F. prausnitzii com-
pared to non-inflamed mucosa.49 Furthermore,
low abundance of Faecalibacterium in postopera-
tive ileal mucosa has been associated with a higher
risk of recurrence,64 and also associated with
a massive increase of leukocytes in UC.66 This
bacterium can metabolize host-derived polysac-
charides (pectin, uronic acids) and other substrates
(such as N-acetyl glucosamine) from the intestinal
mucus for growth, and it is also described as an
important anti-inflammatory commensal
bacterium.38 The anti-inflammatory properties of
F. prausnitzii have been associated with inhibition
of the NF-κB pathway via protein production in
intestinal epithelial cells, while a decrease in pro-
portions of Butyricicoccus pullicaecorum seems to
attenuate trinitrobenzene sulfonic acid (TNBS)-
induced colitis in rats and to increased transe-
pithelial resistance.36 This depletion of
Faecalibacterium and Butyricicoccus, but also of
Ruminococcus hominis, combined with alterations
in bacterial products, especially butyrate,53,57,62
provides the appropriate conditions to allow
E. coli to proliferate.39
Verrucomicrobia phylum, akkermansia
abundance, and its impact on IBD
Unlike for other mucolytic bacteria, some studies
reported a reduction in the levels of Akkermansia
muciniphila in both CD and UC patients and in
the early onset of CD.67,71 It has been proposed
that A. muciniphila could be responsible for exa-
cerbated gut inflammation in IBD patients.
However, a recent study using animal models
did not find any correlation between short-term
intestinal inflammation and the presence of the
bacterium in the gut.72 A. muciniphila use mucus
as a carbon, nitrogen, and energy source, and
therefore, as a consequence of its metabolism, it
produces short-chain fatty acids (acetate, propio-
nate, 1,2-propanediol, and succinate).73 It is
worth mentioning that short-chain fatty acids
seem to be depleted in IBD patients.74
Furthermore, as specifically described for UC
patients, the decrease in the abundance of the
genus Akkermansia and the low abundance of
A. muciniphila could affect the use of mucins as
a carbon source by other symbiotic commensal
bacteria,36 and it was proposed as a possible mar-
ker of dysbiosis.75 Reductions in Akkermansia
genus were also described in the gut microbiota
of patients with CD.56
CDI and IBD: gut microbiota relationships and
implications for disease treatment with fecal
microbiota transplantation
Only a few studies have investigated the specific
impact of CDI on the IBD microbiota. A previous
study76 directly compared the gut microbiota of
IBD patients with and without CDI disease. The
authors found that in patients with both IBD and
CDI, there was a loss of bacterial cooperation in
the gut ecosystem as well as a more pronounced
intestinal dysbiosis than in patients suffering from
only IBD. Metabolite production is also altered in
the inflamed gut, which is essential for several
metabolic processes, as energy production and
host immunity.77 Among these metabolites, buty-
rate has a fundamental role in maintaining the
balance of the intestinal microbiota, with the pre-
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servation of the epithelial barrier and regulation of
the immunity.53,74 Butyric acid, along with acetic
acid and propionic acid are the end products of
indigested carbohydrates in the intestine after bac-
terial fermentation. It was demonstrated that buty-
rate enhances the intestinal barrier function by
facilitating the assembly of tight junctions.78
Butyrate producers supply energy to gut epithelial
cells and therefore they protect against inflamma-
tion and infection.79 In the last decade, several
studies have focused on the modification of the
gut microbiota to successfully treat several intest-
inal diseases, including IBD and CDI. Among the
various taxa investigated, it seems that positive
results are obtained when the feces include the
following taxa: Clostridium clusters IV and XIVa,
which include the Ruminococcaceae and
Lachnospiraceae families, respectively, and the
genera Roseburia, Oscillibacter, Blautia, and
Dorea. This selection of microbes has important
underlying metabolic mechanisms, specially the
production of butyrate in the gut.80
Blautia and Dorea genera: role in maintenance
and recovery of gut homeostasis
In concomitant IBD and CDI diseases, there is
a specific reduction in two groups of bacteria,
Blautia and Dorea. Members of Blautia (butyrate-
producing bacterial species) are already signifi-
cantly reduced in patients with only IBD, but it
seems that the decrease in the relative proportions
in the gut is more marked when the disease is
aggravated with CDI.76 The Blautia genus (espe-
cially Blautia obeum) is selected among the bacter-
ial species enriched in the fecal microbiota of
healthy donors for fecal microbiota transplant
(FMT) and was also found after successful restora-
tion of the gut in patients with recurrent CDI.81–85
Furthermore, in vitro analysis has shown
a negative correlation between the production of
a bile metabolism enzyme (bile salt hydrolase, of
which Blautia is one of the representative produ-
cers) and C. difficile germination.86,87 It was
recently described that the bacterial strain
B. obeum A2-162 produces a lantibiotic, nisin O,
in the human gastrointestinal tract, which presents
antimicrobial activity against both Clostridium per-
fringens and C. difficile.88 Therefore, its depletion
would favor C. difficile colonization and infection
in the IBD gut.
Regarding the Dorea genus, its depletion has been
previously reported in studies investigating patients
suffering from CDI and IBD separately.40,79 Blautia
and Dorea have been described as major acetate
producers in the normal gut, but it is hypothesized
that they are replaced when CDI occurs.79 Recently,
a study proposed a cocktail of bacteria to treat recur-
rent CDI, which includes Blautia producta
(Peptostreptococcus productus), E. coli and
Clostridium bifermentans. The authors demonstrate
in their work that this bacteriotherapy could antag-
onize chronic relapse of CDI, which in turn inhibited
the growth of Bacteroides species.89
Undesirable increase of some taxa: proliferation
of other pathogens and aggravating factors of
disease
There are some taxa that seem to increase in
abundance in patients suffering from IBD and
CDI, including some species of Clostridium,
Enterococcus, and R. gnavus,76 which have also
been described to increase in patients with IBD
(Table 2). High abundances of Proteobacteria and
Enterobacteriaceae are often found in patients
with recurrent CDI82 but also in those suffering
from IBD.37–40,46 Within these two bacterial
groups, some species are classified as important
pathogens, such as Salmonella and enterohemor-
rhagic E. coli, which may take advantage of the
intestinal conditions under dysbiosis to proliferate
and worsen the disease.39 These intestinal condi-
tions include altered oxygen availability and
nitrate production. Under inflammatory condi-
tions, epithelial cells reduce their capacity to
undergo beta-oxidation, resulting in an increase
in available oxygen and a reduction in hydrogen
levels.40 Furthermore, the depletion of butyrate-
producing bacteria favors the expression of Nos2
(an important gene encoding nitrite oxidase
synthase), resulting in elevated levels of available
nitrate and proliferation of the Enterobacteriaceae
family, especially E. coli.90
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After fecal microbiota transplantation for CDI
treatment, an increase in Bacteroidetes to the det-
riment of Protobacteria was found.91 The impor-
tant role of Proteobacteria in IBD and CDI
diseases is associated with its direct role as
a disruptor of intestinal homeostasis and its direct
implication in the inflammation of the intestine.
The absence of differentiated B-cells and defi-
ciency in the production of specific IgA (specifi-
cally targeting Proteobacteria) is correlated with
the persistence of Proteobacteria in the inflamed
gut.92 Other taxonomical alterations related to
CDI and IBD are increased levels of
Fusobacterium and Mycobacterium taxa.93 The
Fusobacteriaceae family has also been found in
high proportions in the gut microbiota of patients
with CD and UC.40,75 Mycobacterium avium subs.
Paratuberculosis and Fusobacterium nucleatum
have been recently investigated as potential aggra-
vating factors for IBD.94
Altered intestinal barrier function and
C. difficile colonization
The impairment of intestinal barrier function or
disruption of mucosal T cells by inflammatory med-
iators favor C. difficile colonization and toxin pro-
duction. Some phospholipids, such as
phosphatidylcholine and phosphatidylethanola-
mine, are released during this disruption.
Phosphatidylcholine is converted into ethanolamine
and glycerol by bacterial phosphodiesterases.
C. difficile benefits from the breakdown of ethanola-
mine and utilizes it as a source of nitrogen and
carbon.95,96 On the other hand, a higher glycosidase
activity has been reported in IBD patients than in
healthy subjects. Indeed, disruption of intestinal bar-
rier function and the intestinal microbiota also
entails the liberation of monosaccharides, which
promote the multiplication and colonization of
C. difficile.96 A previous study described in depth
how C. difficile catabolises microbiota-liberated
mucosal carbohydrates and how pathogen expan-
sion is even aided by microbiota-induced elevation
of sialic acid levels in vivo.97
C. difficile is able to produce para-cresol (p-cre-
sol) through the fermentation of tyrosine in the gut.
A recent study demonstrated that this ability pro-
vides a competitive advantage over other gut bac-
teria, including E. coli, Klebsiella oxytoca, and
Bacteroides thetaiotaomicron.98 Further studies
have proposed that bacterial metabolites, such as
p-cresol, ammonium, and hydrogen sulfide, notably
affect intestinal barrier function and participate in
the IBD course.99
Other microbiota signatures and metabolic
pathways associated with specific conditions and
populations of CDI and IBD
In pediatric population, it has been described that
IBD patients with CDI and with a previous history of
surgery presented a reduction of Ruminococcus,
Alistipes, and Bifidobacterium.100 Even if there are
significant differences in the gut microbiota between
pediatric patients and adults due to the gut micro-
biota is not yet fully developed, throughout this
review we have observed several discrepancies
among the different studies in relation to the pre-
sence of some species of Bifidobacterium and
Ruminococcus and their role in the inflamed mucosa
(Tables 1 and 2). It has been demonstrated that some
strains of R. gnavus are able to assimilate mucin
monosaccharides, to use sialic acid and to produce
propanol and propionate.101 As previously
described, mucin users are implicated in gut
inflammation.37 But the finding that not all of
R. gnavus strains are able to grow on mucin as the
sole carbon source101 may explain the differences
about its depletion or increase in IBD and CDI
disease. Further explanations for an overexpression
of Bifidobacterium,61,68,102 Ruminococcus,49,61,67 or
even Akkermansia102 in the inflamed gut include
the important role of the modifications in the intest-
inal micro-environment, as, for example, an increase
of mucus production,102 and also microbiota mod-
ifications and interactions with aging.
Other three studies have confirmed the reduc-
tion of Alistipes in pediatric patients with
IBD,37,52,56 but also in patients with CDI.102
Alistipes has been associated with protection
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against CDI and positive modulate the immune
response against experimental colitis in mouse
models.103 Furthermore, it has been proposed as
biomarker of CDI,102 and used as one of the
dominant genera in the fecal bacterial composition
of donors for fecal microbiota transplantation to
treat CDI, resulting in the successful integration of
this bacterial group in the gut ecosystem of the
patient.104
Finally, and in relation with metabolic path-
ways, a further analysis showed a reduction in
methionine biosynthesis in IBD patients with
C. difficile after surgery.100 Alterations of sulfur
and cysteine/methionine metabolism in IBD
patients have been previously related to changes
in proportions of some bacteria with specific func-
tions involving these pathways,105 including
F. prausnitzii and Roseburia among others.100
Furthermore, it has been observed that
a commercial form of methionine (available as
dietary supplement) enhances the viability of
Saccharomyces boulardii in the gut, especially in
acidic environments. This nonpathogenic yeast is
classified as a probiotic and it has been used to
prevent CDI106 and suggested as a treatment of
IBD. Furthermore, serological antibodies Anti-
Saccharomyces have been used as a marker for
prediction of CD disease course, within other vari-
ables and patient characteristics.107
Microbiota and treatments for IBD and CDI:
situation and perspective
As already described in this review, one of the
most proposed options in recent years have been
fecal microbiota transplantation to restore the
altered gut ecosystem. We can find in the literature
several studies describing its use in CDI patients
with underlying IBD.108 In a previous study treat-
ing patients with CDI and concurrent IBD, the
effectiveness of FMT was between 79% and 88%,
after one and two interventions, respectively.109
A further study also reported the efficacy of FMT
to treat recurrent CDI in IBD, but authors found
that more than half of patients required IBD treat-
ment escalation shortly after FMT.110 Similarly, in
the study of Khoruts et al.111 results showed that
FMT was less effective in IBD patients suffering
recurrent CDI than in those without IBD, as more
than 25% of the studied IBD patients have
a disease flare following FMT, especially in those
cases with extensive colon involvement, and they
required a treatment with prednisone. Hypothesis
about the problems with FMT in these patients
include implantation of the major taxa in the gut
and deficiency in host immune defenses.111
Meighani et al.112 found a good response to FMT
in patients with CDI and IBD. In their study, three
patients who failed therapy had newly diagnosis of
IBD and one presented severe active disease.
Therefore, authors conclude that FMT is a good
alternative treatment for well-controlled IBD
patients with recurrent CDI.
Consistent with the microbiota changes
observed in IBD and CDI patients, a specific
microbiota signature for fecal microbiota donors
has been described80,113 (Table 3). The selection of
microbes has important underlying metabolic
mechanisms, such as the production of butyrate
in the gut, as largely described in the section
above.
A previous study selected a total of 37 bacteria
to treat dysbiosis during CDI, which could be
administrated orally in a noninvasive way.85 In
this contest, some problems derived from FMT
are related to the actual method of the feces deliv-
ery, which may require colonoscopy and
sedation.116 In addition, other problems could
include the degree of engraftment and immune
response to the transplanted microbiota (donor-
recipient incompatibilities), stemming from an
underlying genetic factor.80 A previous study sug-
gested only a marginal risk of worsening in FMT-
treated IBD patients, and hypothesized the role of
donors to induce remission or to induce worsen-
ing in IBD activity.117 Other described complica-
tions include the transmission of parasites from
donors to patients by FMT, but without gastroin-
testinal symptomatology.118 A recent study used
washed microbiota transplantation in mice and
concluded that the technique avoids the virus
transmission among other complications and is
safer than crude FMT.119
In addition to FMT, probiotic nutrition with
multiple strains for gastrointestinal health modu-
lation has been proposed as an effective and safe
treatment.120 One recent study proposed the strain
Bacillus licheniformis to treat colitis, which seems
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Table 3. Group of bacteria modifications associated with CDI and IBD. Main characteristics and role in disease and fecal microbiota
transplant treatment.
Bacteria group
at genus level Taxonomy
Main characteristics and
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Table 3. (Continued).
Bacteria group
at genus level Taxonomy
Main characteristics and
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to modulate the gut microbiota composition and
has been associated with a decrease in
Bacteroidetes.121 Other probiotics classically used
in different trials to reduce intestinal inflammation
are Lactobacillus rhamnosus, Lactobacillus plan-
tarum, Lactobacillus acidophilus, and Enterococcus
faecium. However, the available results on their
effectiveness in both CD and UC are still not
concise.122 To prevent the likelihood of incurring
CDI, a combination of various probiotics, includ-
ing Streptococcus faecalis, Bacillus mesentericus,
and Clostridium butyricum,123 has been proposed
(once again, we can find among “protective”
strains those associated with butyric acid
Table 3. (Continued).
Bacteria group
at genus level Taxonomy
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◊ According to Bergey´s Manual of Systematics of Archea and Bacteria.
∇ Specific studies addressing the efficacy of different bacterial species in the restoration of the gut microbiota after inflammation and/or infection.
CDI: Clostridium difficile infection.
AM: animal model.
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production). Competition for the niche with non-
toxigenic C. difficile strains has also been suggested
for CDI prevention. Bacillus clausii and
Lactobacillus reuteri also act as probiotics for this
infection because they secrete compounds that
directly inhibit C. difficile.124 Those probiotics pro-
posed for CDI and IBD separately could be used
jointly to treat both diseases. However, a recent
study underlines the important role of mutual
interaction of probiotics, which can inhibit other
probiotics or protective taxa in the gut.125
Therefore, further studies addressing these meta-
bolic interactions are necessary to better under-
stand the role of these probiotics in both diseases.
Conclusions and future directions
In this review, we have summarized the gut micro-
biota changes associated with both forms of IBD
and CDI and their similarity with the dysbiosis
that occurs in the CDI. IBD is itself
a complicated and poorly understood disease.
The alteration of the microbiota and the metabolic
environment of the gut have direct consequences
in chronic inflammation and in the colonization
and multiplication of opportunistic pathogens,
with C. difficile being one of the most important
causes of infection in this group. Our analysis
reveals important modifications in specific taxa
that recur in both diseases despite the intrinsic
differences of each study (variable environment,
genetic diversity, medication usage, smoking his-
tory, and variable diet). Furthermore, the investi-
gation of the metabolic pathways of these groups
of bacteria reveals the specific mechanism of
action in the epithelial cells and lumen in the
gut. Elucidating the impact of bacterial metabolites
in other microbial communities, it is possible to
better discern between protective bacteria and
those that cause harm. All the advances in new
sequencing technologies have provided a large
number of publications that apply these methods
to better understand intestinal inflammation.
However, in this review, we highlight that there
is an insufficient number of studies addressing the
microbiota composition and its changes in the gut
of patients suffering from both CDI and IBD.
Furthermore, the only available data are focused
either on the epidemiology and treatment of the
infection in IBD patients or on the microbiota
composition of adult patients, but there are no
results on other patient groups, such as the elderly,
pediatric, or pregnant IBD populations. In addi-
tion, the results regarding adults are scarce and
supported by only a few studies. Therefore, there
is an urgent need to develop new research lines
addressing the changes in the gut microbiota in
IBD patients suffering from CDI. These studies
will provide results that are now necessary to
develop new therapeutic strategies to prevent and
treat C. difficile and its infection in IBD.
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